Literature DB >> 10608021

Coumadin Aspirin Reinfarction Study: Rationale and Design of the CARS Study.

.   

Abstract

Acute myocardial infarction remains the leading cause of death in the United States. Following increased recognition of the role of thrombosis in the pathogenesis of myocardial infarction, both antiplatelet and anticoagulant therapy have been proven effective in preventing recurrent infarction. However, the optimal antithrombotic regimen remains undetermined. In particular, the role of combination antithrombotic therapy has not been studied. The Coumadin Aspirin Reinfarction Study (CARS) will compare the safety and efficacy of fixed-dose combination Coumadin plus aspirin versus aspirin alone among 8000 survivors of acute myocardial infarction. Patients will be followed for up to 4 years. CARS will provide important information regarding the optimal antithrombotic regimen for myocardial infarct survivors.

Entities:  

Year:  1995        PMID: 10608021     DOI: 10.1007/bf01062707

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  32 in total

1.  AN ASSESSMENT OF LONG-TERM ANTICOAGULANT ADMINISTRATION AFTER CARDIAC INFARCTION. SECOND REPORT OF THE WORKING PARTY ON ANTICOAGULANT THERAPY IN CORONARY THROMBOSIS TO THE MEDICAL RESEARCH COUNCIL.

Authors:  E RICE-WRAY
Journal:  Br Med J       Date:  1964-10-03

2.  Long-term anticoagulant therapy after myocardial infarction. Final report of the Veterans Administration cooperative study.

Authors:  R V Ebert
Journal:  JAMA       Date:  1969-03-24       Impact factor: 56.272

3.  A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group.

Authors: 
Journal:  Lancet       Date:  1980-11-08       Impact factor: 79.321

4.  Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study.

Authors:  T W Meade; S Mellows; M Brozovic; G J Miller; R R Chakrabarti; W R North; A P Haines; Y Stirling; J D Imeson; S G Thompson
Journal:  Lancet       Date:  1986-09-06       Impact factor: 79.321

Review 5.  Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group.

Authors:  V Fuster; M L Dyken; P S Vokonas; C Hennekens
Journal:  Circulation       Date:  1993-02       Impact factor: 29.690

6.  Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death.

Authors:  M J Davies; J M Bland; J R Hangartner; A Angelini; A C Thomas
Journal:  Eur Heart J       Date:  1989-03       Impact factor: 29.983

7.  Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin.

Authors:  C R Klimt; G L Knatterud; J Stamler; P Meier
Journal:  J Am Coll Cardiol       Date:  1986-02       Impact factor: 24.094

8.  Platelet aggregation, coronary artery disease progression and future coronary events.

Authors:  J Y Lam; J G Latour; J Lespérance; D Waters
Journal:  Am J Cardiol       Date:  1994-02-15       Impact factor: 2.778

9.  Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

Authors:  A Hamsten; U de Faire; G Walldius; G Dahlén; A Szamosi; C Landou; M Blombäck; B Wiman
Journal:  Lancet       Date:  1987-07-04       Impact factor: 79.321

10.  Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group.

Authors: 
Journal:  Lancet       Date:  1994-02-26       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.